GLP3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
AOD-9604 stacks well with growth hormone secretagogues like CJC-1295 and Ipamorelin that work through different mechanisms
There was also no long-term follow-up to assess if any delayed complications (for example, abnormal tissue growth or tumor formation) occurred after the injection
Some people start with weekly injections to restore their levels and then transition to a monthly schedule for maintenance
When combined with caloric restriction: the same study's diet-plus-injection arm showed 3.2 kg (7 pounds) additional loss versus diet-plus-placebo at 12 weeks, which was statistically significant (p=0.03)
Baseline labs (B12, folate, metabolic panel, kidney function) are recommended before starting